RMB 3.57 Billion Deal: Laekna Therapeutics Licenses PI3Kα Inhibitor LAE118 to Vasque Bio for Global Rights (Excluding China)

SHANGHAI — Laekna Therapeutics, a Chinese innovative biotech firm, has completed a cross-border licensing deal to advance its self-developed drug candidate LAE118, marking a major step in its global business layout. On June 9, the company announced it has granted U.S.-based Vasque Bio exclusive global development, manufacturing and commercialization rights to LAE118 — a novel pan-mutant selective PI3Kα inhibitor — covering all regions worldwide except China, together with all relevant intellectual property and exploitation rights.

In return, Laekna Therapeutics is entitled to receive a non-refundable and non-creditable upfront cash payment of USD 10 million, as well as the right to acquire up to a double-digit percentage equity stake in Vasque Bio's issued ordinary shares without additional consideration, or alternatively, a cash payment in lieu of such ordinary shares.

Under the license agreement, Laekna Therapeutics is also entitled to receive development and sales milestone payments totaling up to $517 million (bringing the total potential value of the collaboration to $527 million, approximately RMB 3.57 billion), as well as tiered royalties ranging from single-digit to double-digit percentages based on future net sales of LAE118 within the licensed territory.

If Vasque Bio enters into a qualified strategic collaboration or acquisition transaction that meets specific conditions (related to the use of LAE118), Laekna Therapeutics shall be entitled to receive additional payments, up to 50% of the value of such strategic transaction.

As the core asset of this licensing deal, LAE118 is a novel allosteric pan-mutant selective PI3Kα inhibitor independently developed by Laekna Therapeutics. Distinguished from traditional subtype-selective PI3K inhibitors currently on the market by its differentiated molecular design, comprehensive global patent portfolio, and impressive preclinical efficacy data, LAE118 is suitable for development in both solid tumors and rare diseases. With prominent pipeline differentiation advantages, it stands as one of the core candidate assets in Laekna Therapeutics' oncology small-molecule pipeline.

From the perspectives of target mechanism and unmet clinical needs, PIK3CA is a top-tier oncogenic kinase gene with high mutation frequency in solid tumors. Abnormal activation of the PI3Kα protein encoded by this gene leads to sustained downstream activation of the AKT/mTOR pathway, driving tumor cell proliferation and metastasis, while also inducing resistance to targeted therapies.

Clinical data indicate that nearly 40% of patients with HR+/HER2- breast cancer harbor hotspot mutations in the helical or kinase domains of PIK3CA, with a higher mutation prevalence observed among patients in China. Patients with these mutations exhibit poorer prognoses following endocrine and targeted therapies, along with a significantly elevated risk of recurrence. First- and second-generation PI3Kα inhibitors lack mutation selectivity and concurrently inhibit wild-type PI3Kα, readily inducing dose-limiting adverse events such as hyperglycemia and gastrointestinal toxicity. Consequently, clinical dosing is constrained, and long-term safety profiles remain a significant concern.

Compared with traditional subtype-selective PI3K inhibitors, LAE118 achieves mechanistic optimization: the drug precisely targets two major oncogenic mutation sites of PI3Kα, providing comprehensive inhibition of high-frequency mutant subtypes including E542K, E545K, and H1047R. It blocks the activation of mutant pathways at ultra-low doses while barely interfering with the physiological functions of wild-type proteins, thereby reducing off-target toxicity at the source.

Leveraging its differentiated advantages, preclinical studies of this drug were selected for presentation at the 2025 AACR Annual Meeting and publicly disclosed at the 2024 San Antonio Breast Cancer Symposium (SABCS). In xenograft tumor models, LAE118 demonstrated superior antitumor activity compared to existing pan-mutant inhibitors in the same class, while also exhibiting excellent oral pharmacokinetic properties and metabolic stability, highlighting its potential as a best-in-class therapy.

Currently, the clinical development of LAE118 is progressing efficiently and smoothly, with all regulatory submissions successfully completed. In December 2024, the core preclinical efficacy data of the pipeline was officially released. In December 2025, Laekna Therapeutics published patent WO2025247348, covering the core compound structure of LAE118, thereby completing a closed-loop intellectual property layout both domestically and internationally. In January 2026, it received Investigational New Drug (IND) approval from the U.S. FDA, followed by IND approval from China's Center for Drug Evaluation (CDE) in May of the same year, achieving dual approvals in China and the United States. Global Phase I clinical development has now officially commenced.

Since 2026, the global race for pan-mutant selective PI3Kα inhibitors has entered a period of explosive deal activity, with leading pharmaceutical companies heavily investing in next-generation mutation-selective drugs, driving continuous valuation increases in the sector.

In terms of licensing deals, in March this year, Novartis paid a $2 billion upfront payment and up to $1 billion in milestone payments to acquire Pikavation Therapeutics, Inc., a wholly-owned subsidiary of Synnovation. The latter possesses a portfolio of pan-mutant selective PI3Kα inhibitor projects, including SNV4818. This licensing deal for assets with the same target has directly raised the global valuation benchmark for similar pipeline transactions, further reinforcing industry recognition of the trend toward mutant-selective PI3Kα inhibitors replacing traditional inhibitors.

From a commercialization perspective, Roche's PI3Kα inhibitor Inavolisib received FDA approval in 2024 for the treatment of PIK3CA-mutated, HR+/HER2- locally advanced or metastatic breast cancer worldwide. Although Inavolisib demonstrates improved safety compared to first-generation PI3Kα inhibitors, some patients still experience adverse events such as hyperglycemia and rash, and its efficacy may be limited against certain rare or specific mutation subtypes.

In addition to multinational corporations (MNCs) such as Novartis, Eli Lilly, and Roche, overseas biotech companies—including Relay Therapeutics, Synnovation, and Totus Medicines—are accelerating the development of next-generation pan-mutant selective PI3Kα inhibitors, with frequent clinical advancements and financing activities.

At the domestic pharmaceutical company level, Haihe Pharmaceuticals, Changchun High-Tech, and Junshi Biosciences are simultaneously laying out differentiated pipelines targeting the same mechanism, intensifying competition in this therapeutic area. Cross-disease indications and dual-indication strategies have become the core approach for Chinese-developed pipelines to break through.

Compared with similar drugs under development, LAE118 leverages this international expansion to segment domestic and overseas markets, simultaneously capturing share in the two niche sectors of oncology and rare diseases, extending the drug's lifecycle, and realizing dual value extraction from a single pipeline.

Specifically, in the Chinese market, the focus is on advanced and metastatic PIK3CA-mutated solid tumors. LAE118 targets breast cancer as its core initial indication, while simultaneously expanding into derived indications for gynecologic cancers and gastrointestinal solid tumors, aligning with the urgent clinical needs for precision oncology therapy in China.

In overseas markets, the assignee, Vasque Bio, is a U.S.-based clinical-stage biotech company focused on the research and development of innovative drugs for severe rare diseases. It has no oncology drug pipeline, and its team possesses deep expertise in the full spectrum of overseas rare disease clinical trial design, orphan drug applications, and international commercialization.

Meanwhile, backed by TCG and F-Prime, two top-tier North American life sciences venture capital firms, the company boasts ample capital reserves and the capability to rapidly advance clinical development of rare disease drugs and execute capital operations. This aligns perfectly with Laekna's needs for developing differentiated overseas indications for LAE118, resulting in complete complementarity between the two parties in terms of business, resources, and strategic focus.

Furthermore, this licensing deal adopts the increasingly mature NewCo collaboration model. Compared to the traditional one-time rights sale (License-out) model, the core advantages of this licensing transaction are streamlined and intuitive:

First, Laekna Therapeutics retains core rights in China, securing its position in the domestic oncology market. Second, by combining equity stakes with derivative M&A benefits, the deal moves beyond fixed consideration constraints to lock in long-term value appreciation from the overseas pipeline. Third, clear delineation of responsibilities in R&D, clinical development, and commercialization allows both parties to leverage their respective strengths, reducing overall development risk while balancing short-term cash flow needs with long-term asset value. This transaction structure is well-suited to meet the global development and commercialization demands for broader indications.

Overall, the international launch of LAE118 not only validates Laekna Therapeutics' pipeline value and licensing deal commercialization capabilities, but also serves as a typical case of the global expansion strategy for next-generation Chinese PI3Kα innovative drugs. Furthermore, investment, financing, and licensing activity in the PI3Kα sector are unlikely to cool down in the short term. Against the backdrop of intensifying competition among homogeneous oncology pipelines, the model of splitting pipeline assets for broad-indication licensing-out, combined with a lightweight NewCo structure for international expansion, will become an efficient strategic choice for Chinese small-molecule innovative drugs going global.